FBRX Forte Biosciences Inc
Price (delayed)
$7.35
Market cap
$48.38M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$12.17
Enterprise value
$26.13M
Forte Biosciences, Inc. is a clinical stage, dermatology company developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and
Highlights
FBRX's EPS has soared by 51% YoY and by 25% QoQ
The equity has grown by 49% YoY
FBRX's quick ratio is down by 37% year-on-year
The net income has contracted by 13% YoY and by 3.8% from the previous quarter
Key stats
What are the main financial stats of FBRX
Market
Valuations
Earnings
Shares outstanding
6.58M
Market cap
$48.38M
Enterprise value
$26.13M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.2
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$36.6M
Net income
-$35.48M
EBIT
-$35.48M
EBITDA
-$35.44M
Free cash flow
-$30.78M
Per share
Balance sheet
Liquidity
EPS
-$12.17
EPS diluted
-$12.17
Free cash flow per share
-$10.56
Book value per share
$35.9
Revenue per share
$0
TBVPS
$21.11
Total assets
$61.56M
Total liabilities
$9.08M
Debt
$0
Equity
$52.48M
Working capital
$52.27M
Debt to equity
0
Current ratio
6.76
Quick ratio
6.43
Net debt/EBITDA
0.63
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-103.1%
Return on equity
-132%
Return on invested capital
-1,017.8%
Return on capital employed
-67.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
FBRX stock price
How has the Forte Biosciences stock price performed over time
Intraday
-1.08%
1 week
-10.37%
1 month
-19.23%
1 year
-59.03%
YTD
-67.64%
QTD
-5.28%
Financial performance
How have Forte Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$36.6M
Net income
-$35.48M
Gross margin
N/A
Net margin
N/A
The operating income has contracted by 13% YoY and by 2.7% from the previous quarter
The net income has contracted by 13% YoY and by 3.8% from the previous quarter
Growth
What is Forte Biosciences's growth rate over time
Valuation
What is Forte Biosciences stock price valuation
P/E
N/A
P/B
0.2
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
FBRX's EPS has soared by 51% YoY and by 25% QoQ
The price to book (P/B) is 94% lower than the 5-year quarterly average of 3.3 and 77% lower than the last 4 quarters average of 0.9
The equity has grown by 49% YoY
Efficiency
How efficient is Forte Biosciences business performance
FBRX's return on equity is down by 40% year-on-year but it is up by 13% since the previous quarter
The company's return on assets fell by 27% YoY but it rose by 13% QoQ
Dividends
What is FBRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for FBRX.
Financial health
How did Forte Biosciences financials performed over time
The company's total liabilities has surged by 148% YoY and by 6% QoQ
FBRX's total assets has surged by 58% year-on-year
Forte Biosciences's debt is 100% less than its equity
The equity has grown by 49% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.